Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / GMAB - Genmab to launch late-stage study of epcoritamab in lymphoma


GMAB - Genmab to launch late-stage study of epcoritamab in lymphoma

Genmab A/S (GMAB) announces the initiation of a 480-subject Phase 3 clinical trial comparing bispecific antibody (simultaneously binds to CD3 and CD20) epcoritamab to chemo in patients with diffuse large B-cell lymphoma ((DLBCL)). The primary endpoint is overall survival.The company is co-developing the candidate with AbbVie (ABBV) under an agreement inked five months ago.GMAB is up 3% premarket on light volume while ABBV is up 1%.

For further details see:

Genmab to launch late-stage study of epcoritamab in lymphoma
Stock Information

Company Name: Genmab A/S
Stock Symbol: GMAB
Market: NASDAQ
Website: genmab.com

Menu

GMAB GMAB Quote GMAB Short GMAB News GMAB Articles GMAB Message Board
Get GMAB Alerts

News, Short Squeeze, Breakout and More Instantly...